Holen Sie sich die Stockscreener-App
239.42
1.99%
4.68
Handel nachbörslich:
239.88
0.46
+0.19%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt RMD?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$234.74
Offen:
$234.91
24-Stunden-Volumen:
740.50K
Relative Volume:
0.77
Marktkapitalisierung:
$34.99B
Einnahmen:
$4.81B
Nettoeinkommen (Verlust:
$1.11B
KGV:
38.87
EPS:
6.16
Netto-Cashflow:
$1.35B
1W Leistung:
-3.73%
1M Leistung:
-0.24%
6M Leistung:
+9.54%
1J Leistung:
+60.75%
1-Tages-Spanne:
$234.91
$240.22
1-Wochen-Bereich:
$231.17
$249.26
52-Wochen-Spanne:
$148.03
$260.49
Resmed Inc Stock (RMD) Company Profile
Firmenname
Resmed Inc
Sektor
Telefon
(858) 746-2400
Adresse
9001 SPECTRUM CENTER BLVD., SAN DIEGO, CA
Vergleichen Sie RMD mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| RMD | 239.42 | 34.99B | 4.81B | 1.11B | 1.35B | 6.16 |
| ISRG | 531.64 | 190.09B | 7.87B | 2.24B | 586.00M | 4.25 |
| BDX | 224.10 | 65.14B | 20.18B | 1.73B | 3.07B | 5.51 |
| ALC | 85.81 | 42.44B | 9.76B | 1.16B | 665.00M | 0.72 |
| WST | 307.21 | 22.29B | 2.88B | 499.60M | 321.60M | 7.41 |
Resmed Inc Stock (RMD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-02-06 | Fortgesetzt | KeyBanc Capital Markets | Overweight |
| 2023-10-27 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2023-10-12 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-10-09 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2023-09-29 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2023-09-06 | Hochstufung | Needham | Hold → Buy |
| 2023-09-05 | Herabstufung | UBS | Buy → Neutral |
| 2023-08-01 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-05-23 | Eingeleitet | UBS | Buy |
| 2023-04-14 | Eingeleitet | Mizuho | Buy |
| 2023-01-17 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2022-10-28 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-10-20 | Hochstufung | BofA Securities | Neutral → Buy |
| 2022-10-12 | Eingeleitet | Jefferies | Hold |
| 2022-09-08 | Hochstufung | Citigroup | Neutral → Buy |
| 2022-08-15 | Herabstufung | CLSA | Buy → Outperform |
| 2022-08-12 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-08-12 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2022-08-12 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-06-06 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-04-06 | Eingeleitet | Wolfe Research | Outperform |
| 2022-01-31 | Hochstufung | Citigroup | Neutral → Buy |
| 2022-01-31 | Hochstufung | Goldman | Neutral → Buy |
| 2022-01-28 | Hochstufung | RBC Capital Mkts | Underperform → Sector Perform |
| 2022-01-24 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2022-01-24 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2022-01-13 | Hochstufung | CLSA | Outperform → Buy |
| 2022-01-13 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2021-12-21 | Hochstufung | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2021-12-06 | Hochstufung | Macquarie | Neutral → Outperform |
| 2021-10-22 | Hochstufung | CLSA | Underperform → Outperform |
| 2021-08-02 | Herabstufung | CLSA | Outperform → Sell |
| 2021-08-02 | Herabstufung | Needham | Buy → Hold |
| 2021-07-28 | Hochstufung | Jefferies | Underperform → Hold |
| 2021-07-26 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2021-07-14 | Eingeleitet | RBC Capital Mkts | Underperform |
| 2021-06-28 | Herabstufung | Citigroup | Buy → Neutral |
| 2021-06-22 | Hochstufung | Macquarie | Neutral → Outperform |
| 2021-06-22 | Eingeleitet | Robert W. Baird | Neutral |
| 2021-06-21 | Bestätigt | Needham | Buy |
| 2021-06-16 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2021-06-09 | Hochstufung | CLSA | Sell → Outperform |
| 2021-05-21 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2021-05-11 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-04-30 | Herabstufung | Citigroup | Buy → Neutral |
| 2021-03-16 | Hochstufung | Needham | Hold → Buy |
| 2020-11-02 | Hochstufung | UBS | Neutral → Buy |
| 2020-10-30 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2020-10-27 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2020-08-07 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-06-17 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-05-01 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2020-05-01 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2020-02-18 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-02-03 | Eingeleitet | CLSA | Underperform |
| 2020-01-31 | Herabstufung | UBS | Buy → Neutral |
| 2020-01-10 | Eingeleitet | Oppenheimer | Perform |
| 2019-11-22 | Eingeleitet | KeyBanc Capital Markets | Sector Weight |
| 2019-07-29 | Hochstufung | UBS | Neutral → Buy |
| 2019-07-16 | Herabstufung | UBS | Buy → Neutral |
| 2019-05-06 | Hochstufung | UBS | Neutral → Buy |
| 2019-04-18 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2019-01-25 | Herabstufung | Goldman | Buy → Neutral |
| 2019-01-25 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2018-10-26 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2018-07-02 | Eingeleitet | Goldman | Buy |
Alle ansehen
Resmed Inc Aktie (RMD) Neueste Nachrichten
Top broker says buy ResMed and this ASX 200 share - The Motley Fool Australia
Publication relating to transparency notifications, Business Wires News - AsiaOne
Nyxoah’s Voting Rights Shift with ResMed Stake - TipRanks
Publication relating to transparency notifications - The Manila Times
ResMed's Stake in Nyxoah Drops Below 5% Threshold in Latest Holdings Update | NYXH Stock News - StockTitan
ResMed Inc. (NYSE:RMD) Shares Acquired by Mawer Investment Management Ltd. - MarketBeat
ResMed's (NYSE:RMD) earnings growth rate lags the 11% CAGR delivered to shareholders - Yahoo Finance
ResMed Is 80 And 80: Hits 80-Plus Relative Strength Rating After Rising 80% In A Year - Yahoo! Voices
ResMed (ASX:RMD) 3-Year EBITDA Growth Rate : 11.10% (As of Sep. 2024) - GuruFocus.com
KBC Group NV Increases Holdings in ResMed Inc. (NYSE:RMD) - MarketBeat
ResMed Inc. stock rises Friday, outperforms market - MarketWatch
What is Zacks Research's Forecast for ResMed Q1 Earnings? - MarketBeat
Sumitomo Mitsui Trust Group Inc. Increases Position in ResMed Inc. (NYSE:RMD) - MarketBeat
ResMed Inc. stock falls Thursday, underperforms market - MarketWatch
Insider Sale: Director Witte De Sells Shares of ResMed Inc (RMD) - GuruFocus.com
ResMed director Jan De Witte sells shares worth $198,052 - Investing.com
ResMed Inc Insider Sells Shares, Retains Ownership - MSN
What is Zacks Research's Forecast for ResMed Q2 Earnings? - MarketBeat
Insiders At ResMed Sold US$16m In Stock, Alluding To Potential Weakness - Yahoo Finance Australia
Baillie Gifford & Co. Lowers Stake in ResMed Inc. (NYSE:RMD) - MarketBeat
Versor Investments LP Sells 2,400 Shares of ResMed Inc. (NYSE:RMD) - MarketBeat
ResMed CFO Brett Sandercock sells $249,000 in stock - Investing.com India
ResMed Inc. stock falls Wednesday, underperforms market - MarketWatch
OVERSEA CHINESE BANKING Corp Ltd Has $4.75 Million Holdings in ResMed Inc. (NYSE:RMD) - MarketBeat
Entropy Technologies LP Invests $1.87 Million in ResMed Inc. (NYSE:RMD) - MarketBeat
Shareholders May Not Be So Generous With ResMed Inc.'s (NYSE:RMD) CEO Compensation And Here's Why - Simply Wall St
ResMed’s Peter Farrell Adjusts Stock Holdings - TipRanks
ResMed Inc Director Adjusts Stock Holdings - TipRanks
ResMed’s Executive Stock Transactions Highlight Compensation Practices - TipRanks
ResMed Inc. CEO Executes Strategic Stock Transactions - TipRanks
ResMed Inc’s Executive Share Transactions Revealed - TipRanks
ResMed CFO Sandercock Sells 1,000 Shares - TipRanks
ResMed Inc. stock falls Tuesday, underperforms market - MarketWatch
ResMed Updates Dividend Details for ASX CDI Holders - TipRanks
Zacks.com featured highlights include Greenbrier, Walmart, Leidos, InterDigital and ResMed - Yahoo Finance
ResMed Inc. (NYSE:RMD) Shares Bought by Principal Financial Group Inc. - MarketBeat
Resmed Inc Announces Upcoming Stock Sale - TipRanks
ResMed Inc. Officer Plans Major Stock Sale - TipRanks
Los Angeles Capital Management LLC Lowers Holdings in ResMed Inc. (NYSE:RMD) - MarketBeat
This Insider Just Sold Shares of ResMed Inc - GuruFocus.com
ResMed Inc. (NYSE:RMD) Shares Sold by XY Capital Ltd - MarketBeat
Insider Sale: Director Peter Farrell Sells Shares of ResMed Inc (RMD) - GuruFocus.com
ResMed's chairman emeritus Peter C. Farrell sells $497,480 in stock - Investing.com
Peter C. Farrell Sells 2,000 Shares of ResMed Inc. (NYSE:RMD) Stock - MarketBeat
ResMed Inc. (NYSE:RMD) Shares Sold by Tandem Investment Advisors Inc. - MarketBeat
With 74% ownership, ResMed Inc. (NYSE:RMD) boasts of strong institutional backing - Yahoo Finance
QRG Capital Management Inc. Boosts Stock Position in ResMed Inc. (NYSE:RMD) - MarketBeat
Revolve announces CEO transition - MSN
ResMed Inc. stock rises Thursday, outperforms market - MarketWatch
ResMed share price jumps 10% on strong quarterly update - MSN
Radnor Capital Management LLC Takes $903,000 Position in ResMed Inc. (NYSE:RMD) - MarketBeat
Finanzdaten der Resmed Inc-Aktie (RMD)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.80%
2.31%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):